Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;31(10):1101-1107.
doi: 10.1080/13543784.2022.2130750. Epub 2022 Oct 8.

Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)

Affiliations
Free article

Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)

Aaron Wetten et al. Expert Opin Investig Drugs. 2022 Oct.
Free article

Abstract

Introduction: Generic fibrates are used off-label as add-in therapy for the management of primary biliary cholangitis (PBC) but with unproven long-term liver-related survival benefits. The recently developed fibrate, seladelpar, has shown promising results in clinical trials, but these outcomes have been previously marred by safety concerns.

Areas covered: We summarize existing treatment options in PBC and evaluate current trial data for seladelpar in relation to liver biochemistry, symptomology, and safety.

Expert opinion: Seladelpar leads to marked improvement in liver biochemistry and may improve symptoms. Safety concerns around liver toxicity appear to have been addressed. With likely increasing evidence compared to existing off-label fibrates, seladelpar has the potential as an attractive future second-line agent in PBC.

Keywords: PPAR; Primary biliary cholangitis; fatigue; fibrates; peroxisome proliferator-activated receptor agonists; pruritus; seladelpar.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

LinkOut - more resources